NeuroSense Therapeutics is developing PrimeC, a fixed-dose combination drug of ciprofloxacin and celecoxib, to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. This approach targets multiple underlying mechanisms of these complex conditions, addressing the significant unmet medical need for effective treatments.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases are complex conditions with multiple underlying mechanisms and limited effective treatments, creating a significant unmet medical need. Current therapeutic strategies often fail to address the multiple pathways affected by these conditions.
Solution
NeuroSense Therapeutics is a clinical-stage pharmaceutical company developing PrimeC, a fixed-dose combination drug of ciprofloxacin and celecoxib, as a combined therapeutic strategy for ALS and other neurodegenerative diseases. PrimeC is designed to target multiple pertinent mechanisms involved in these complex diseases. It has been successfully tested in a Phase 2a clinical trial in ALS patients, demonstrating efficacy, safety, and tolerability in the Phase 2b PARADIGM clinical trial, highlighting PrimeC’s significant impact on slowing down disease progression and increasing survival rates. The company is preparing to commence a pivotal Phase 3 clinical study, in parallel to exploring commercial approval from Health Canada.
Target Audience
The primary target audience includes individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, as well as healthcare providers specializing in neurology and neurodegenerative disorders.
Features
- Fixed-dose combination of ciprofloxacin and celecoxib
- Targets multiple underlying mechanisms of ALS and other neurodegenerative diseases
- Demonstrated efficacy, safety, and tolerability in a Phase 2a clinical trial
- Significant impact on slowing down disease progression and increasing survival rates (PARADIGM trial)
- Granted orphan drug designation from both the U.S. FDA and the European Medicines Agency (EMA)
- Strong patent estate with coverage out to 2042